Keywords: Pfizer, Ablynx, Ozoralizumab, Rheumatoid arthritis, First-quarer 2011 results

Pfizer Ph II study confirms efficacy of Ablynx' ozoralizumab in RA

Article | 20 May 2011

Belgian drug developer Ablynx (Euronext Brussels: ABLX) revealed  top-line results from the recently completed proof-of-concept Phase II clinical trial ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Ablynx

Pfizer

Go to company listing

Related Drugs

ozoralizumab

Go to drug listing